These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 15052543)
1. Anti-insulin-like growth factor strategies in breast cancer. Jerome L; Shiry L; Leyland-Jones B Semin Oncol; 2004 Feb; 31(1 Suppl 3):54-63. PubMed ID: 15052543 [TBL] [Abstract][Full Text] [Related]
2. Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer. Byron SA; Yee D Semin Oncol; 2003 Oct; 30(5 Suppl 16):125-32. PubMed ID: 14613033 [TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factors and breast cancer therapy. Zeng X; Yee D Adv Exp Med Biol; 2007; 608():101-12. PubMed ID: 17993235 [TBL] [Abstract][Full Text] [Related]
4. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer. Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006 [TBL] [Abstract][Full Text] [Related]
5. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Sachdev D; Yee D Mol Cancer Ther; 2007 Jan; 6(1):1-12. PubMed ID: 17237261 [TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factors in breast cancer. Helle SI; Lønning PE Acta Oncol; 1996; 35 Suppl 5():19-22. PubMed ID: 9142960 [TBL] [Abstract][Full Text] [Related]
7. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048 [TBL] [Abstract][Full Text] [Related]
8. The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential. Bieghs L; Johnsen HE; Maes K; Menu E; Van Valckenborgh E; Overgaard MT; Nyegaard M; Conover CA; Vanderkerken K; De Bruyne E Oncotarget; 2016 Jul; 7(30):48732-48752. PubMed ID: 27129151 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Rozen F; Pollak M Int J Oncol; 1999 Sep; 15(3):589-94. PubMed ID: 10427145 [TBL] [Abstract][Full Text] [Related]
10. Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. Favoni RE; de Cupis A; Bruno S; Yee D; Ferrera A; Pirani P; Costa A; Decensi A Br J Cancer; 1998 Jun; 77(12):2138-47. PubMed ID: 9649125 [TBL] [Abstract][Full Text] [Related]
11. Fucoidan downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells. Kim IH; Nam TJ Oncol Rep; 2018 Mar; 39(3):1516-1522. PubMed ID: 29328495 [TBL] [Abstract][Full Text] [Related]
12. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Werner H; Le Roith D Crit Rev Oncog; 1997; 8(1):71-92. PubMed ID: 9516087 [TBL] [Abstract][Full Text] [Related]
13. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights. Li H; Batth IS; Qu X; Xu L; Song N; Wang R; Liu Y Mol Cancer; 2017 Jan; 16(1):6. PubMed ID: 28137302 [TBL] [Abstract][Full Text] [Related]
14. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546 [TBL] [Abstract][Full Text] [Related]
15. Biological & physiological aspects of action of insulin-like growth factor peptide family. Pavelić J; Matijević T; Knezević J Indian J Med Res; 2007 Apr; 125(4):511-22. PubMed ID: 17598937 [TBL] [Abstract][Full Text] [Related]
16. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Song RX; Zhang Z; Chen Y; Bao Y; Santen RJ Endocrinology; 2007 Aug; 148(8):4091-101. PubMed ID: 17525128 [TBL] [Abstract][Full Text] [Related]
17. Clinical studies in humans targeting the various components of the IGF system show lack of efficacy in the treatment of cancer. Philippou A; Christopoulos PF; Koutsilieris DM Mutat Res Rev Mutat Res; 2017; 772():105-122. PubMed ID: 28528684 [TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). Lu Y; Zi X; Zhao Y; Mascarenhas D; Pollak M J Natl Cancer Inst; 2001 Dec; 93(24):1852-7. PubMed ID: 11752009 [TBL] [Abstract][Full Text] [Related]
19. GPER, IGF-IR, and EGFR transduction signaling are involved in stimulatory effects of zinc in breast cancer cells and cancer-associated fibroblasts. Pisano A; Santolla MF; De Francesco EM; De Marco P; Rigiracciolo DC; Perri MG; Vivacqua A; Abonante S; Cappello AR; Dolce V; Belfiore A; Maggiolini M; Lappano R Mol Carcinog; 2017 Feb; 56(2):580-593. PubMed ID: 27341075 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation. Hermanto U; Zong CS; Wang LH Cell Growth Differ; 2000 Dec; 11(12):655-64. PubMed ID: 11149601 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]